Please login to the form below

Not currently logged in
Email:
Password:

market share

This page shows the latest market share news and features for those working in and with pharma, biotech and healthcare.

Roche's O’Day swaps big pharma for big biotech

Roche's O’Day swaps big pharma for big biotech

Gilead is still a dominant player in HIV – although its jostling for market share with ViiV.

Latest news

  • Dutch biotech Argenx claims $1.8bn licensing deal with J&J Dutch biotech Argenx claims $1.8bn licensing deal with J&J

    In that market the companies have agreed to share economics 50/50 on a royalty basis, while Argenx will get double-digit sales royalties elsewhere.

  • GSK buys cancer firm Tesaro for $5.1bn GSK buys cancer firm Tesaro for $5.1bn

    of the year – gives GSK rights to approved PARP inhibitor Zejula (niraparib), which is jostling for market share with AstraZeneca's Lynparza (olaparib) and Clovis Oncology's Rubraca (rucaparib). ... third quarter – well behind the $438m posted by

  • Shire’s angioedema drug Takhzyro claims EU approval Shire’s angioedema drug Takhzyro claims EU approval

    that launched last year and has been trying to steal market share from Cinryze, which is administered intravenously twice a week. ... Analysts at Bernstein recently predicted that Takhzyro will eventually dominate the HAE prophylaxis market with a 70%

  • MSD claims EU approval for two HIV products MSD claims EU approval for two HIV products

    Company battles back against dominant Gilead and GSK. Merck &Co/MSD’s market share in HIV has been on the slide thanks to tough competition from GlaxoSmithKline and Gilead, but it ... The two products are due to roll out onto the market in the first

  • Roche enters NASH race with deal to buy Jecure Roche enters NASH race with deal to buy Jecure

    Company joins Novartis, Pfizer and others in nascent market. Roche has joined the melee of pharma companies trying to claim a share of the market for non-alcoholic steatohepatitis (NASH) drugs, ... Some predictions put the market potential at $20bn to

More from news
Approximately 0 fully matching, plus 470 partially matching documents found.

Latest Intelligence

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    and a series of sweeping reforms is now opening China’s pharma market to rapid modernisation. ... Obstacles remain. There remain some major potential pitfalls for pharma companies competing for a share of this rapidly-expanding market.

  • The race for a HIV ‘cure’ The race for a HIV ‘cure’

    GSK’s majority-owned ViiV Healthcare is the strongest challenger to Gilead’s 52% market share. ... bringing it to market if it is totally uninteresting and of no need to patients,” said Elliott.

  • Trust me, I’m from pharma Trust me, I’m from pharma

    Industry invests hugely in innovation, with it costing around £1.1b to bring a product to market. ... Instead of focusing commercial strategies on market share or product sales, companies need to develop a granular understanding on the issues that

  • Marketing

  • Market research

More from intelligence
Approximately 1 fully matching, plus 59 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • OUTiCO win Best in UK Pharmaceutical Outsourcing award

    They combine unique accessibility data and the latest digital tools to flexibly deploy exceptional sales professionals in Market Access, Secondary Care, and Primary Care projects. ... And, if you haven’t read these case studies yet, take a look:  .

  • Seduce anyone in four simple steps

    share. People are icebergs. The critical bit is invisible, under the water line. ... Flirt a little by testing the findings within the market. The best seductions use imagination.

  • Creativity has lost its worth

    advertising creativity and business success, and that high levels of creativity make advertising campaigns some 12 times more efficient at increasing a brand’s market share.”. ... shift to short-termism, and lower campaign budgets leading to lower

  • Where is health behaviour change heading?

    control. Yet on a personal/psychological basis, technology offers us an unprecedented chance to communicate findings and share knowledge - i.e. ... to market in a way that other industries do.  According to the MM&M annual survey of 2015,   digital

  • How Transparent Is Transparency?

    development, the clinical trials programmes and the cost of those products that don’t come to market, which are effectively written-off. ... Are pharma companies spending a proportionate amount to their product portfolio, their market share, and sales

More from PMHub
Approximately 1 fully matching, plus 32 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics